Alnylam Pharmaceuticals
Every trial this sponsor leads in the registry, and everything it has published.
22 active · 31% of this sponsor’s registry footprint
Not shown above: 2 Phase 1 healthy-volunteer trials and 1 trial whose condition matched no therapy area.
Trials by phase
Pipeline by phase · 13 drugs in active development
Phase 3 · 3 drugs
Phase 2 · 4 drugs
Active trials only, code names and brands merged. 40 completed trials are in the counts above but their drugs are not folded into this pipeline.
Disease landscapes · 3 of 10 curated
Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.
Track your drug now for free
We check every one of its trials daily and tell you what moved.
- Status changeStatus moved to completedWas recruiting · always alerts
- Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
- New trialNew trial registered in your scopeFirst posted within 30 days
- Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
- Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English